Showing 3521-3530 of 5646 results for "".
- EMA Review Finds Rare Risk of Vision Loss Associated With Semaglutide Medicineshttps://modernod.com/news/ema-review-finds-rare-risk-of-vision-loss-associated-with-semaglutide-medicines/2482842/The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines following concerns about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAIO
- Harrow Acquires US Commercial Rights to Byqlovi for Postoperative Inflammation and Painhttps://modernod.com/news/harrow-acquires-us-commercial-rights-to-byqlovi-for-postoperative-inflammation-and-pain/2482841/Harrow and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement in which Harrow has acquired the exclusive US commercial rights for Byqlovi (clobetasol propionate ophthalmic suspension) 0.05%. Financial terms of the deal were not d
- Navigate Patient Solutions Adds Ophthalmology Leaders to its Medical Advisory Boardhttps://modernod.com/news/navigate-patient-solutions-adds-ophthalmology-leaders-to-its-medical-advisory-board/2482835/Navigate Patient Solutions announced the addition of Vance Thompson, MD; David Cox, and Matthew P. Jensen to its Medical Advisory Board. Navigate is developing a patient engagement solution for ophthalmology. The startup partners with ophthal
- Haag-Streit Launches Cornea Map Toric Assessment Feature for the Lenstarhttps://modernod.com/news/haag-streit-launches-cornea-map-toric-assessment-feature-for-the-lenstar/2482833/Haag-Streit has unveiled the the cornea map for its flagship Lenstar 900 optical biometer. This feature is designed to provide clinic
- FDA Accepts Tenpoint's New Drug Application for Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/fda-accepts-tenpoints-new-drug-application-for-brimochol-pf-for-the-treatment-of-presbyopia/2482832/Tenpoint Therapeutics announced that the FDA has accepted the new drug application (NDA) for Brimochol PF for the treatment of presbyopia. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026. The FDA noted that it is not planning to hold an advisory co
- iVeena Submits IND Application to the FDA for Phase 2 Clinical Trial for Pediatric Myopiahttps://modernod.com/news/iveena-submits-ind-application-to-the-fda-for-phase-2-clinical-trial-for-pediatric-myopia/2482830/iVeena Delivery Systems announced the submission of an investigational new drug (IND) application to the FDA for IVMED-85 for the treatment of pediatric myopia. IVMED-85 is a new chemical entity (NCE), p
- CIRM Awards $4.7 Million for Vision Loss Gene Therapyhttps://modernod.com/news/cirm-awards-47-million-for-vision-loss-gene-therapy/2482827/The California Institute for Regenerative Medicine (CIRM) awarded $4.7 million to Blue Gen Therapeutics Foundation (Principal Investigator Aaron Nagiel, MD, PhD) to fund preclinical research that aims to develop a gene therapy for the rare disease blue cone monochromacy (BCM). <
- EssilorLuxottica to Acquire European Ophthalmology Network Optegra Clinicshttps://modernod.com/news/essilorluxottica-to-acquire-ophthalmology-network-optegra-clinics/2482825/EssilorLuxottica and MidEuropa have entered into an agreement in which EssilorLuxottica will acquire Optegra, an integrated ophthalmology platform operating in five European markets: the UK, Czech Republic, Poland, Slovakia and the Netherlands. Financial terms of the deal were
- Alcon Receives FDA Approval of Tryptyr for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/alcon-receives-fda-approval-of-tryptyr-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2482823/Alcon announced that the FDA has approved Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of dry eye disease (DED). Tryptyr is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal senso
- Ocular Therapeutix To Close Enrollment this Week for SOL-R Trial Evaluating Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-to-close-enrollment-this-week-for-sol-r-trial-evaluating-axpaxli-in-wet-amd/2482822/Ocular Therapeutix announced that enrollment in the SOL-R registrational trial of its product candidate Axpaxli in wet age-related macular degeneration (AMD) will close this week. “Completing enrollment in SOL-R—the largest retinal TKI trial to date—one year